Special Program for Research and Training in Tropical Diseases

Special Program for Research and Training in Tropical Diseases
Name	Special Program for Research and Training in Tropical Diseases
Formation	1978
Founder	World Health Organization, United Nations Development Programme, World Bank
Type	Intergovernmental organization
Headquarters	Geneva
Region served	Global South
Parent organization	World Health Organization

Special Program for Research and Training in Tropical Diseases is an international health initiative established to coordinate research and training on neglected tropical diseases. It was created through collaboration among major multilateral institutions to address public health challenges in regions such as Africa, South America, and Southeast Asia. The program has engaged with academic centers, pharmaceutical manufacturers, and philanthropic foundations to support clinical trials, capacity building, and policy development.

History and Establishment

The program originated from a 1970s policy dialogue involving World Health Organization, United Nations Development Programme, and World Bank leaders influenced by advocates including Kenneth Warren, James Grant, and researchers from Rockefeller Foundation. Early meetings convened experts from institutions such as London School of Hygiene & Tropical Medicine, Harvard School of Public Health, University of Oxford, and Institut Pasteur. Formal launch aligned with global health initiatives like the Alma-Ata Declaration and paralleled efforts by UNICEF, Bill & Melinda Gates Foundation, and national agencies such as Centers for Disease Control and Prevention and National Institutes of Health. The program’s formative years featured coordination with disease-specific efforts like the Onchocerciasis Control Programme and campaigns against malaria led by actors including PATH and Find (Foundation for Innovative New Diagnostics).

Mission and Objectives

The program’s mission emphasizes research, capacity development, and policy translation to reduce disease burden in endemic regions. Objectives include supporting basic science at places like Wellcome Trust funded labs, clinical research at Johns Hopkins University and Karolinska Institutet, and training programs linked to Makerere University, Universidad de São Paulo, and Mahidol University. It aims to inform multilateral strategies used by Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, and national ministries such as Ministry of Health (Brazil) and Ministry of Health (India) while engaging regulatory bodies like European Medicines Agency and Food and Drug Administration.

Organizational Structure and Governance

Governance has involved steering committees and advisory boards with representation from World Health Organization, UNDP, and World Bank alongside academic leaders from University of California, San Francisco, Imperial College London, and Peking University. Scientific advisory panels have included specialists affiliated with London School of Hygiene & Tropical Medicine, Stockholm University, and Swiss Tropical and Public Health Institute. Secretariat operations have coordinated with regional offices in Addis Ababa, Brasília, Manila, and New Delhi and liaised with networks such as TDR Global and consortia like European & Developing Countries Clinical Trials Partnership. Oversight mechanisms referenced standards from International Committee of Medical Journal Editors, Good Clinical Practice, and intergovernmental accords like the International Health Regulations (2005).

Research and Training Programs

Research portfolios encompassed parasitology projects at Institut Pasteur, vector control studies with inputs from Rockefeller Foundation, and drug development collaborations with Novartis, Merck & Co., and GSK. Training initiatives partnered with universities including University of Cape Town, University of Nairobi, and Universidad Nacional Autónoma de México to deliver curricula on clinical epidemiology, entomology, and pharmacology. Programs supported field trials in collaboration with Médecins Sans Frontières, national institutes such as Bangladesh Institute of Tropical and Infectious Diseases, and laboratory networks coordinated with Pasteur Institute Network. Capacity building drew on methods promoted by World Bank projects and philanthropic models from Wellcome Trust and Howard Hughes Medical Institute.

Partnerships and Collaborations

The program worked closely with global health actors like Bill & Melinda Gates Foundation, Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, and PATH, and engaged with pharmaceutical partners including Merck Sharp & Dohme, AstraZeneca, and Sanofi. Academic collaborations spanned University of Ghana, Centro de Investigaciones en Salud, and Mahidol University, while operational partnerships included WHO Regional Office for Africa, PAHO, and African Development Bank. It coordinated with disease-specific networks such as the Malaria Atlas Project, Onchocerciasis Elimination Program for the Americas, and research consortia like the European Malaria Vaccine Initiative.

Funding and Resource Allocation

Funding sources combined multilateral contributions from World Bank loans, programmatic support from United Nations Development Programme, grants from Bill & Melinda Gates Foundation and Wellcome Trust, and industry in-kind donations from Merck & Co. and Novartis. Resource allocation prioritized endemic-country capacity strengthening at institutions like Makerere University and University of Ibadan, clinical trial support in sites overseen by Centers for Disease Control and Prevention and National Institutes of Health, and procurement partnerships involving UNICEF and UNDP. Fiscal oversight referenced standards used by International Monetary Fund grant mechanisms and reporting to stakeholders including bilateral donors such as USAID and DFID.

Impact and Criticism

The program contributed to advances in diagnostics, drug trials, and training that influenced policies at World Health Organization and national ministries in Nigeria, India, and Brazil. Outputs informed control strategies for diseases including leishmaniasis, schistosomiasis, and lymphatic filariasis, and supported clinical evaluations that engaged companies like GlaxoSmithKline and research centers like Ifakara Health Institute. Criticism arose regarding prioritization, with commentators from The Lancet and analysts at Chatham House and Brookings Institution questioning resource distribution, representation of researchers from Global South institutions, and industry influence linked to partners such as Pharmaceutical Research and Manufacturers of America. Debates invoked ethical oversight standards from Council for International Organizations of Medical Sciences and calls for greater transparency from civil society groups including Médecins Sans Frontières and Oxfam.

Category:Global health organizations